4D Molecular Therapeutics (FDMT) Receivables - Other (2021 - 2022)

4D Molecular Therapeutics (FDMT) has reported Receivables - Other for 3 consecutive years, with $700000.0 the latest figure, recorded in Q4 2022.

• In Q4 2022, Receivables - Other changed 0.0% year-over-year to $700000.0; the TTM figure through Dec 2022 stood at $700000.0 (changed 0.0% YoY), while the FY2022 annual figure was $700000.0, changed 0.0% from the prior year.
• Receivables - Other steadied at $700000.0 in Q4 2022 per FDMT's latest filing, from $700000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $700000.0 in Q4 2021 and bottomed at $149000.0 in Q4 2019.
• Historically, Receivables - Other has averaged $527500.0 across 3 years, with a median of $630500.0 in 2021.
• On a YoY basis, Receivables - Other climbed as much as 0.0% in 2022 and fell as far as 0.0% in 2022.
• 4D Molecular Therapeutics' Receivables - Other stood at $149000.0 in 2019, then jumped by 369.8% to $700000.0 in 2021, then changed by 0.0% to $700000.0 in 2022.
• Business Quant data shows FDMT's Receivables - Other at $700000.0 in Q4 2022, $700000.0 in Q4 2021, and $561000.0 in Q1 2021.